Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies.

Pharmaceutical Medicine
Shazia K Nakhoda, Anthony J Olszanski

Abstract

The incorporation of checkpoint inhibitors into the treatment armamentarium of oncologic therapeutics has revolutionized the course of disease in many cancers. This has spurred the evaluation of other novel immunotherapy agents in clinical trials with varying levels of success. This review explores possible explanations for differences in efficacy in clinical outcomes among currently US FDA-approved immunotherapy agents, lessons learned from clinical trial failures of investigational immunotherapies, and methods to improve success in the future. An inherent challenge of early phase immunotherapy trials is identifying the maximum tolerated dose and improving understanding of the pharmacokinetics/pharmacodynamics of immunotherapies as they exert their effects indirectly via T cells rather than directly via dose-dependent cytotoxic activity. The wide heterogeneity of the immune system among patients and within an individual patient over time largely affects the results of optimal dose- and toxicity-finding studies as well as the effectiveness of immunotherapy. Therefore, optimization of phase I/II study design is crucial for clinical trial success. These differences may also help elucidate the lack of immunotherapy benefit in cert...Continue Reading

References

Mar 5, 2005·The New England Journal of Medicine·Elizabeth HorstmannChristine Grady
Feb 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckChristian Manegold
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jan 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoni RibasAxel Hauschild
Feb 1, 2014·Nature Reviews. Immunology·Adrian Liston, Daniel H D Gray
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Oct 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susan E BatesEric H Rubin
Oct 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bostjan SerugaIan F Tannock
Dec 17, 2015·JAMA : the Journal of the American Medical Association·Stephan EhrhardtCurtis L Meinert
May 15, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K YamazakiI Hyodo
Jul 21, 2016·Journal for Immunotherapy of Cancer·Leisha A EmensHoward L Kaufman
Jan 15, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maitreyee HazarikaRichard Pazdur
Feb 10, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amy BaroneRichard Pazdur
Feb 27, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Meredith K ChukRichard Pazdur
Mar 9, 2017·The Lancet Oncology·Lesley SeymourUNKNOWN RECIST working group
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Sep 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J MessenheimerBernard A Fox
Oct 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason ChesneyHoward L Kaufman
Oct 11, 2017·Nature Reviews. Immunology·Arlene H Sharpe, Kristen E Pauken
Jan 11, 2018·British Journal of Cancer·Russell W JenkinsKeith T Flaherty
Mar 23, 2018·Annals of the New York Academy of Sciences·Kohei Shitara, Hiroyoshi Nishikawa
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Aug 24, 2018·Journal for Immunotherapy of Cancer·Nolan A WagesKatherine S Panageas
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Michael J OvermanMichael A Morse
Sep 29, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tara C MitchellThomas F Gajewski
Jan 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckJulie R Brahmer
Feb 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul NghiemSuzanne L Topalian
Feb 21, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neal ReadySuresh S Ramalingam
Feb 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Celeste LebbéJacopo Pigozzo
Mar 22, 2019·Journal for Immunotherapy of Cancer·Geoffrey T GibneyJeffrey S Weber

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

iRECIST
SECOMBIT

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.